1175 related articles for article (PubMed ID: 28007626)
1. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
Ding PN; Lord SJ; Gebski V; Links M; Bray V; Gralla RJ; Yang JC; Lee CK
J Thorac Oncol; 2017 Apr; 12(4):633-643. PubMed ID: 28007626
[TBL] [Abstract][Full Text] [Related]
2. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
Takeda M; Okamoto I; Nakagawa K
Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957
[TBL] [Abstract][Full Text] [Related]
3. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
4. Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
Yang Z; Hackshaw A; Feng Q; Fu X; Zhang Y; Mao C; Tang J
Int J Cancer; 2017 Jun; 140(12):2805-2819. PubMed ID: 28295308
[TBL] [Abstract][Full Text] [Related]
5. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
6. Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations.
Haspinger ER; Agustoni F; Torri V; Gelsomino F; Platania M; Zilembo N; Gallucci R; Garassino MC; Cinquini M
Crit Rev Oncol Hematol; 2015 May; 94(2):213-27. PubMed ID: 25523487
[TBL] [Abstract][Full Text] [Related]
7. Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.
Burotto M; Manasanch EE; Wilkerson J; Fojo T
Oncologist; 2015 Apr; 20(4):400-10. PubMed ID: 25795635
[TBL] [Abstract][Full Text] [Related]
8. A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.
Moran T; Palmero R; Provencio M; Insa A; Majem M; Reguart N; Bosch-Barrera J; Isla D; Costa EC; Lee C; Puig M; Kraemer S; Schnell D; Rosell R
Lung Cancer; 2017 Jun; 108():154-160. PubMed ID: 28625629
[TBL] [Abstract][Full Text] [Related]
9. Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
Horn L; Gettinger S; Camidge DR; Smit EF; Janjigian YY; Miller VA; Pao W; Freiwald M; Fan J; Wang B; Chand VK; Groen HJM
Lung Cancer; 2017 Nov; 113():51-58. PubMed ID: 29110849
[TBL] [Abstract][Full Text] [Related]
10. Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
Liang W; Wu X; Fang W; Zhao Y; Yang Y; Hu Z; Xue C; Zhang J; Zhang J; Ma Y; Zhou T; Yan Y; Hou X; Qin T; Dinglin X; Tian Y; Huang P; Huang Y; Zhao H; Zhang L
PLoS One; 2014; 9(2):e85245. PubMed ID: 24533047
[TBL] [Abstract][Full Text] [Related]
11. Optimized selection of three major EGFR-TKIs in advanced EGFR-positive non-small cell lung cancer: a network meta-analysis.
Zhang Y; Sheng J; Yang Y; Fang W; Kang S; He Y; Hong S; Zhan J; Zhao Y; Xue C; Ma Y; Zhou T; Ma S; Gao F; Qin T; Hu Z; Tian Y; Hou X; Huang Y; Zhou N; Zhao H; Zhang L
Oncotarget; 2016 Apr; 7(15):20093-108. PubMed ID: 26933807
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
13. Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
Landi L; Tiseo M; Chiari R; Ricciardi S; Rossi E; Galetta D; Novello S; Milella M; D'Incecco A; Minuti G; Tibaldi C; Salvini J; Facchinetti F; Haspinger ER; Cortinovis D; Santo A; Banna G; Catino A; GiajLevra M; Crinò L; de Marinis F; Cappuzzo F
Clin Lung Cancer; 2014 Nov; 15(6):411-417.e4. PubMed ID: 25242668
[TBL] [Abstract][Full Text] [Related]
14. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib.
Lee VH; Leung DK; Choy TS; Lam KO; Lam PM; Leung TW; Kwong DL
BMC Cancer; 2016 Feb; 16():147. PubMed ID: 26911310
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non-Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials.
Zhang Y; Zhang Z; Huang X; Kang S; Chen G; Wu M; Miao S; Huang Y; Zhao H; Zhang L
Clin Lung Cancer; 2017 Sep; 18(5):e333-e340. PubMed ID: 28462807
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
[TBL] [Abstract][Full Text] [Related]
18. Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis.
Popat S; Mok T; Yang JC; Wu YL; Lungershausen J; Stammberger U; Griebsch I; Fonseca T; Paz-Ares L
Lung Cancer; 2014 Aug; 85(2):230-8. PubMed ID: 24929780
[TBL] [Abstract][Full Text] [Related]
19. A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer.
Fujiwara A; Yoshida M; Fujimoto H; Nakahara H; Ito K; Nishihama K; Yasuma T; Hataji O; Taguchi O; D'Alessandro-Gabazza CN; Gabazza EC; Kobayashi T
Oncol Res; 2018 Aug; 26(7):1031-1036. PubMed ID: 29321093
[TBL] [Abstract][Full Text] [Related]
20. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study.
Bilgin B; Sendur MAN; Yucel S; Celik E; Ozyukseler DT; Ayhan M; Basoglu T; Ilhan A; Akdeniz N; Gulmez A; Dogan I; Aktas BY; Gurbuz M; Koca S; Paydas S; Tatli AM; Cinkir HY; Alan O; Erol C; Hizal M; Kut E; Menevse S; Sakalar T; Taskaynatan H; Deniz GI; Karaagac M; Avci O; Sen E; Karatas F; Akinci MB; Dede DS; Demir A; Demirkazık A; Oksuzoglu B; Kilickap S; Yumuk F; Yalcin B
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2145-2152. PubMed ID: 33433657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
